CardioVascular BioTherapeutics (fka CVBT)

[JBDC]

Yet another patent granted by USPTO for VT's Ischemic Heart Disease therapy.


It is a comprehensive piece of IP which has 15 different claims to it.
Wow, VT is killing it. Their comprehensive patent portfolio sets it aside from the vast majority of biotech companies.

Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims

As per VT's presentation & the UN WIPO:-

Patents at the Core: the Biotech Business
World Intellectual Property Organisation - WIPO

“Anyone, I would imagine, who has tried
to create a biotech company knows just how important patents are. You learn this when you’re
studying, and again at your first job, and if you haven’t done so before, you realize it the first
time you
meet potential investors.”
Mads Øvlisen, Chairman of the Board of
Directors, Novo Nordisk